182 related articles for article (PubMed ID: 29513759)
1. Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.
Nørgaard CH; Jakobsen LH; Gentles AJ; Dybkær K; El-Galaly TC; Bødker JS; Schmitz A; Johansen P; Herold T; Spiekermann K; Brown JR; Klitgaard JL; Johnsen HE; Bøgsted M
PLoS One; 2018; 13(3):e0193249. PubMed ID: 29513759
[TBL] [Abstract][Full Text] [Related]
2. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.
Bødker JS; Brøndum RF; Schmitz A; Schönherz AA; Jespersen DS; Sønderkær M; Vesteghem C; Due H; Nørgaard CH; Perez-Andres M; Samur MK; Davies F; Walker B; Pawlyn C; Kaiser M; Johnson D; Bertsch U; Broyl A; van Duin M; Shah R; Johansen P; Nørgaard MA; Samworth RJ; Sonneveld P; Goldschmidt H; Morgan GJ; Orfao A; Munshi N; Johnson HE; El-Galaly T; Dybkær K; Bøgsted M
Blood Adv; 2018 Sep; 2(18):2400-2411. PubMed ID: 30254104
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.
Dybkær K; Bøgsted M; Falgreen S; Bødker JS; Kjeldsen MK; Schmitz A; Bilgrau AE; Xu-Monette ZY; Li L; Bergkvist KS; Laursen MB; Rodrigo-Domingo M; Marques SC; Rasmussen SB; Nyegaard M; Gaihede M; Møller MB; Samworth RJ; Shah RD; Johansen P; El-Galaly TC; Young KH; Johnsen HE
J Clin Oncol; 2015 Apr; 33(12):1379-88. PubMed ID: 25800755
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
5. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status.
Ziolkowska E; Wolowiec D; Karpinski P; Blonski JZ; Lech-Maranda E; Borowiec M; Balcerczak E; Sasiadek M; Robak T; Korycka-Wolowiec A
Leuk Lymphoma; 2019 Jun; 60(6):1409-1419. PubMed ID: 30187811
[TBL] [Abstract][Full Text] [Related]
9. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
Friedman DR; Weinberg JB; Barry WT; Goodman BK; Volkheimer AD; Bond KM; Chen Y; Jiang N; Moore JO; Gockerman JP; Diehl LF; Decastro CM; Potti A; Nevins JR
Clin Cancer Res; 2009 Nov; 15(22):6947-55. PubMed ID: 19861443
[TBL] [Abstract][Full Text] [Related]
10. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
11. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
Ertault-Daneshpouy M; Noguera ME; Gisselbrecht C; Haddad A; Brice P; Marolleau JP; Soulier J; Mounier N
Clin Adv Hematol Oncol; 2008 Jan; 6(1):55-63. PubMed ID: 18322442
[TBL] [Abstract][Full Text] [Related]
12. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Schlette EJ; Admirand J; Wierda W; Abruzzo L; Lin KI; O'Brien S; Lerner S; Keating MJ; Tam C
Leuk Lymphoma; 2009 Oct; 50(10):1597-605. PubMed ID: 19863337
[TBL] [Abstract][Full Text] [Related]
13. Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometric immunophenotyping in patients with chronic lymphocytic leukemia.
Sheridan R; Mounajjed T; Ehrmann DE; Hurtubise PE; Schrager JA
Cytometry B Clin Cytom; 2006 Jul; 70(4):320-1. PubMed ID: 16906578
[TBL] [Abstract][Full Text] [Related]
14. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH
Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635
[TBL] [Abstract][Full Text] [Related]
15. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
Nadeu F; Royo R; Clot G; Duran-Ferrer M; Navarro A; Martín S; Lu J; Zenz T; Baumann T; Jares P; Puente XS; Martín-Subero JI; Delgado J; Campo E
Blood; 2021 May; 137(21):2935-2946. PubMed ID: 33211804
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
17. microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.
Negrini M; Cutrona G; Bassi C; Fabris S; Zagatti B; Colombo M; Ferracin M; D'Abundo L; Saccenti E; Matis S; Lionetti M; Agnelli L; Gentile M; Recchia AG; Bossio S; Reverberi D; Rigolin G; Calin GA; Sabbioni S; Russo G; Tassone P; Morabito F; Ferrarini M; Neri A
Clin Cancer Res; 2014 Aug; 20(15):4141-53. PubMed ID: 24916701
[TBL] [Abstract][Full Text] [Related]
18. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.
Gattei V; Bulian P; Del Principe MI; Zucchetto A; Maurillo L; Buccisano F; Bomben R; Dal-Bo M; Luciano F; Rossi FM; Degan M; Amadori S; Del Poeta G
Blood; 2008 Jan; 111(2):865-73. PubMed ID: 17959854
[TBL] [Abstract][Full Text] [Related]
19. Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells.
Smolej L; Vroblova V; Motyckova M; Jankovicova K; Schmitzova D; Krejsek J; Maly J
Neoplasma; 2011; 58(2):140-5. PubMed ID: 21275464
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotyping of subtypes of B-chronic (mature) lymphoid leukemia. A study of 242 cases.
Batata A; Shen B
Cancer; 1992 Nov; 70(10):2436-43. PubMed ID: 1384948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
